文献速递淋巴瘤

在CHOP方案中加入依托泊苷与ALK阳性成人间变性大细胞淋巴瘤结局改善相关:一项北欧淋巴瘤组研究

The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.
PubMed 文献 · Br J Haematol · 2017-05-08

该研究基于丹麦和瑞典淋巴瘤登记处2000至2010年确诊的122例成人(≥18岁)系统性ALK阳性间变性大细胞淋巴瘤患者,分析生存结局与危险因素。中位年龄40岁(范围18-85),5年总生存率和无进展生存率分别为78%和64%。多变量分析中仅骨髓受累与较差无进展生存独立相关(HR=8.57,P<0.001);年龄41-65岁患者接受CHOEP方案与总生存改善相关(HR=0.38,P=0.047)。

要点

  • 队列5年总生存率78%,5年无进展生存率64%。
  • 多变量分析中仅骨髓受累与较差无进展生存独立相关(HR=8.57,P<0.001)。
  • 年龄41-65岁患者接受CHOEP与总生存改善相关(HR=0.38,P=0.047)。

核心结论

  • 作者认为在该年龄组(41-65岁)的ALK阳性间变性大细胞淋巴瘤治疗中,在CHOP方案基础上加用依托泊苷似乎是合理的。

研究设计与样本

  • 基于丹麦和瑞典淋巴瘤登记处的双国人群队列研究,纳入2000至2010年确诊的122例成人(≥18岁)系统性ALK阳性间变性大细胞淋巴瘤患者,占所有淋巴瘤的0.4%。

主要发现

  • 整个队列的中位年龄为40岁(范围18-85岁),5年总生存率为78%,5年无进展生存率为64%。
  • 多变量分析中,仅骨髓受累与较差的无进展生存独立相关(HR=8.57,P<0.001)。
  • 年龄分层显示,41-65岁患者接受CHOEP方案与总生存改善相关,即使校正危险因素后仍相关(HR=0.38,P=0.047)。

临床怎么用

  • 作者认为,对于41-65岁的ALK阳性间变性大细胞淋巴瘤患者,在CHOP方案中加入依托泊苷似乎是合理的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anaplastic large cell lymphomas (ALCLs) are rare CD30+ peripheral T-cell lymphomas (PTCLs) classified according to the expression of the anaplastic lymphoma kinase (ALK+) protein or not (ALK-). We have analysed the outcome and risk factors for survival in a population-based bi-national cohort of patients with systemic ALK+ ALCL. A total of 122 adult (≥18 years) patients diagnosed with ALK+ ALCL between 2000 and 2010 were identified from the Danish and Swedish lymphoma registries, representing 0·4% of all lymphomas. The median age of the cohort was 40 years (range 18-85). The 5-year overall survival and progression-free survival (PFS) was 78% and 64%, respectively. Age was strongly associated with outcome, and only bone marrow (BM) involvement was independently associated with poorer PFS in multivariate analysis (Hazard Ratio [HR] = 8·57, P < 0·001). Age stratification of the patients demonstrated an association between treatment with CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone) and improved overall survival for patients aged 41-65 years, even when adjusted for risk factors (HR = 0·38, P = 0·047). Our results suggest that the addition of etoposide to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) in the treatment for ALK+ ALCL seems reasonable in this age group.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Cederleuf H, Bjerregård Pedersen M, Jerkeman M, et al. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study. Br J Haematol. 2017. PMID: 28485010. doi:10.1111/bjh.14740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。